- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06612372
Effects of 60-day-6° Head-down Bed Rest on Cartilage and Function of the Knee Joint
September 24, 2024 updated by: Peking University Third Hospital
Objective: To investigate the effects of long-term simulated unloading in bed on articular cartilage quality based on functional magnetic resonance imaging (FMRI) and Knee joint function.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
A total of 26 subjects were recruited for a 60-day period of head-down bed rest (HDBR).
The bed rest position is a 6° downward tilt of the head, and all daily activities are performed in this position.
We will perform functional MRI scans of the right knee joint using T2 mapping sequences to assess tissue composition and water content before and after HDBR.
Functional assessments, including the Y-Balance Test and International Knee Documentation Committee (IKDC) scores, were performed pre-HDBR and post-HDBR.We will divide each participant's knee cartilage into 18 regions and measured T2 values according to the whole organ magnetic resonance imaging score (WORMS) partitioning method.
Study Type
Interventional
Enrollment (Estimated)
26
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianquan Wang, M.D.
- Phone Number: 13253137009
- Email: wjqsportsmed@163.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking University Third Hospital
-
Contact:
- Jian-quan Wang, M.D.
- Phone Number: 13801076267
- Email: keny1417@vip.sina.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- (1) male; (2) age 25-50 years old; (3) height between 160-175 cm, weight ≥50kg, and BMI between 18.5-26 kg/m²; (4) good general health status.
Exclusion Criteria:
- (1) history of alcoholism; (2) smoking ≥5 cigarettes/day in the 3 months before the test; (3) drug dependence or use of medications affecting bone metabolism within 2 weeks before screening; (4) presence of metal implants, severe vertigo, or severe snoring.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Long term bed rest intervention group
60-day-6° head-down bed rest
|
Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
T2 mapping
Time Frame: three days before the HDBR started and three days after the HDBR ended
|
metabolic and microstructural changes within the articular cartilage matrix components can be assessed, reflecting collagen fiber structure integrity and water content within the tissue
|
three days before the HDBR started and three days after the HDBR ended
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Y-balance test
Time Frame: three days before the HDBR started and three days after the HDBR ended
|
can comprehensively evaluate an individual's joint range of motion, lower limb strength, sense of balance, and neuromuscular control, as well as the postural control and dynamic stability of lower limbs.
|
three days before the HDBR started and three days after the HDBR ended
|
|
International Knee Documentation Committee (IKDC) scores
Time Frame: three days before the HDBR started and three days after the HDBR ended
|
reflects the highest level of activity that an individual is able to perform.
|
three days before the HDBR started and three days after the HDBR ended
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Jianquan Wang, M.D., Peking University Third Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 10, 2023
Primary Completion (Estimated)
November 10, 2024
Study Completion (Estimated)
November 15, 2024
Study Registration Dates
First Submitted
September 19, 2024
First Submitted That Met QC Criteria
September 24, 2024
First Posted (Actual)
September 25, 2024
Study Record Updates
Last Update Posted (Actual)
September 25, 2024
Last Update Submitted That Met QC Criteria
September 24, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- M2024710
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Weightlessness
-
Centre National d'Etudes SpatialesEuropean Space AgencyCompletedWeightlessness | Weightlessness; Adverse EffectFrance
-
Centre National d'Etudes SpatialesEuropean Space AgencyCompletedWeightlessness | Weightlessness; Adverse EffectFrance
-
Centre National d'Etudes SpatialesCompletedWeightlessness | Weightlessness; Adverse EffectFrance
-
Centre National d'Etudes SpatialesEuropean Space AgencyCompleted
-
National Aeronautics and Space Administration (NASA)CompletedWeightlessnessUnited States
-
Centre National d'Etudes SpatialesCompletedWeightlessness SimulationFrance
-
University Hospital, CaenCentre National d'Etudes Spatiales; The University of New South Wales; Université...UnknownCerebral Blood Flow | WeightlessnessFrance
-
Centre National d'Etudes SpatialesEuropean Space Agency; MEDES - IMPSActive, not recruitingWeightlessness | Simulated Microgravity by Head Down Tilt BedrestFrance
-
Centre National d'Etudes SpatialesEuropean Space Agency; National Space Development Agency, JapanCompletedSimulation of Weightlessness by Anti-Orthostatic Long Term Bed RestFrance
-
Groupe Hospitalier de Bretagne SudCompletedPatient Simulation | High Fidelity Simulation Training | Instructional Virtual Realities | Weightlessness Simulation | Space SimulationFrance
Clinical Trials on 60-day-6° head-down bed rest
-
Chinese PLA General HospitalActive, not recruitingMRI | Neuroplasticity | Microgravity | Repeatable Battery for the Assessment of Neuropsychological StatusChina
-
Centre National d'Etudes SpatialesCompletedWeightlessness SimulationFrance
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
Swedish Orphan BiovitrumAmgenCompleted
-
University of Vermont Medical CenterNot yet recruiting
-
Shenzhen People's HospitalRecruiting
-
University of California, IrvineWithdrawnAnesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries | Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)United States
-
Institut CurieHoffmann-La Roche; Ministry of Health, France; Amgen; Pierre Fabre LaboratoriesActive, not recruitingPrimary Central Nervous System LymphomaFrance
-
Intarcia TherapeuticsCompleted
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbCompletedLeukemia | Acute Lymphoblastic LeukemiaUnited States